Testing a new cholesterol drug in children with high cholesterol
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You weigh more than 40 pounds (18 kg) and have a BMI between 17 and 42.
- You have been diagnosed with heterozygous familial hypercholesterolemia (HeFH).
- Your LDL cholesterol is 130 mg/dL or higher, even with current cholesterol medications.
- You must be on a stable diet and cholesterol medications for at least 6 weeks.
- If you are sexually active, you must use effective birth control (girls) or agree to use condoms or other contraception (boys).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
This study looks at children who may have inherited high cholesterol, especially when one parent is affected. It may help doctors detect the condition earlier and understand how it runs in families.
This study is checking the long-term safety and how well a new injectable medicine (lerodalcibep) works to lower cholesterol in children and teens with familial hypercholesterolemia (an inherited condition causing very high cholesterol). It's for those who already finished an earlier study of this same medicine.
This study tests an investigational medicine called QLC7401 for people with a genetic condition called heterozygous familial hypercholesterolemia, which causes very high cholesterol. It aims to see if the new medicine can further lower bad cholesterol when added to your usual cholesterol treatments.
This study tests an experimental daily pill (enlicitide decanoate) that lowers LDL ('bad') cholesterol in children and teens with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see if this medicine can safely help reduce their high cholesterol levels.
This study tests a new injection called ART002g1 for people with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it is safe and can help lower cholesterol levels.
Hear when a new Familial Hypercholesterolemia - Heterozygous trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.